#Fingerprinting Infants Helps Track Vaccinations in Developing Countries Billions of dollars a year are spent vaccinating children in developing countries
but about half as many immunizations are administered as could be because of unreliable vaccination records. Biometric researchers from Michigan State university have developed a fingerprint-scanning system for children under five years old that could replace ineffective paper vaccination records.
Until now biometrics experts believed fingerprints of babies and toddlers were too unreliable because image sensors are designed for the ridges and valleys of adult fingertips.
Paper-based vaccination records are lost easily and don t reliably provide health workers with up-to-date information on patient history.
The Bill and Melinda Gates Foundation funded the research specifically for recording vaccinations but the patient-identifying system has broader applications says Anil Jain a distinguished professor at Michigan State university s Computer science and Engineering Department and coauthor of the paper.
Compared to the status quo of not getting vaccinations for life-threatening diseases mothers are not asking these questions
These findings lead to the potential of moving from vaccines for specific influenza strains towards developing a protection,
"Our extraordinary breakthrough could lead to the development of a vaccine component that can protect against all new influenza viruses, with the potential for future development of a one-off universal flu vaccine shot,
either through infection or through vaccination. The study was published in the journal Science e
#Now, aircraft wings that can'self heal'on the fly Even the researchers involved in the project describe it as"verging on science fiction".
#This vaccine could help block HIV WASHINGTON: Scientists have designed a new experimental HIV vaccine that may stimulate the immune system to block infection from the deadly virus. New research led by scientists at The Scripps Research Institute (TSRI),
INTERNATIONAL AIDS Vaccine Initiative (IAVI) and the Rockefeller University shows in mice that the vaccine candidate can stimulate the immune system activity necessary to stop HIV infection.
The findings could provide key information for the development of an effective AIDS vaccine, researchers said.
The research, published in the journals Cell and Science, represents a leap forward in the effort to develop a vaccine against HIV
which has struggled so far to elicit antibodies (immune system molecules) that can effectively fight off different strains of the virus."The results are said pretty spectacular
While many vaccines for other diseases use a dead or inactive version of the disease-causing microbe itself to trigger antibody production,
This challenge has led researchers to believe that a successful AIDS vaccine will need a series of related
"The vaccine appears to work well in our mouse model to'prime'the antibody response,
or vaccinating animals.""Till that happens, early diagnosis and prompt treatment is the key
#Vaccine success holds hope for end to deadly scourge of Ebola The world is for the first time on the verge of being able to protect humans against Ebola,
the World health organization (WHO) said on Friday, as data from a trial in Guinea showed a vaccine was 100 percent effective.
Initial results from the trial, which tested Merck and Newlink Genetics'VSV-ZEBOV vaccine on some 4, 000 people who had been in close contact with a confirmed Ebola case,
showed 100 percent protection after 10 days. The results were described as"remarkable"and"game changing"by global health specialists."
"We believe that the world is on the verge of an efficacious Ebola vaccine, "WHO vaccine expert Marie Paule Kieny told reporters in a briefing from Geneva.
The vaccine could now be used to help end the worst recorded outbreak of Ebola, which has killed more than 11,200 people in West Africa
since it began in December 2013. WHO Director-General Margaret Chan said the results, published online in the medical journal The Lancet,
"This and other vaccine trials were tracked fast with enormous international effort as researchers raced to be able to test potential therapies
and vaccines while the virus was still circulating.""We knew it was a race against time
"Ring vaccination"The Guinea trial began on March 23 to evaluate the effectiveness and safety of a single dose of VSV-ZEBOV using a so-called"ring vaccination"strategy,
where close contacts of a person diagnosed with Ebola are immunised-either immediately, or at a later date.
As data began to emerge showing the very high protection rates in those vaccinated immediately,
with all participants receiving the vaccine immediately, and will be extended to include 13-to 17-year-olds and possibly also 6-to 12-year-old children,
which allowed the team in Guinea to assess this vaccine in the middle of an epidemic"."""Our hope is that this vaccine will now help bring this epidemic to an end
and be available for the inevitable future Ebola epidemics, "his statement said. The medical charity Doctors without Borders (MSF),
whom had feared that a sharp decline in cases this year would scupper hopes of proving that a vaccine could work.
as the only real hope for demonstrating the efficacy of a vaccine e
#China plans to enforce real names on Social media Chinese government has issued new regulations to eliminate fake social media accounts.
and vaccination tracking campaigns in resource-poor and field settings. In addition to serving low-resource or remote areas, the researchers noted that intrinsic wireless connectivity can serve epidemic-related studies,
or tracking vaccination campaigns in most resource-poor settings. It fantastic for an undergrad to be first author on the publication.
Thanks to this, the article published today in PLOS ONE describes a new step towards the creation of a vaccine,
This technique could be a much better candidate for a human vaccine. The invention is protected commercially
to start clinical trials on human candidates for preventive vaccination and to cure the disease by combining the vaccine with regenerative therapies.
The Germans Trias Institute plans to carry out these steps with patients at the hospital and to optimize the product by dosage and guideline studies.
which is why the chances of developing an effective vaccine have been deemed low.)They show that this new formulation reduces the minimal curative dose in a disease model, based on infections in mice, by 100-fold and,
#Scientists find molecular switch that creates long-term immunity Melbourne researchers have identified a protein responsible for preserving the antibody-producing cells that lead to long-term immunity after infection or vaccination.
""The hope for a definitive cure and an effective vaccine has been frustrated by HIV's endless propensity to subvert the host's defences
#MERS Not Given Same Vaccine Attention as Ebola, Other Viruses A MERS outbreak has infected about 150 people in South korea,
But a vaccine is not among their tools since it doesn yet exist, and is probably not close to being developed.
has no vaccine, according to the Centers for Disease Control and Prevention. MERS was discovered only in 2012 in Saudi arabia.
However, fewer companies have worked on vaccines and drugs for the MERS virus, according to Reuters. Small biotech companies such as Greffex,
Inovio and Novavax have done all some investigation on vaccines for the sickness but the research is still all preclinical,
Ebola research, including vaccines and treatments, dominated headlines worldwide in the wake of the outbreak of the virus in multiple West african nations last year.
000 doses of its Phase I trial vaccine in Africa. However, other viruses were also acingfor deployment amid the panicked fears as that outbreak spread.
The SARS vaccine work proceeded for years but since the virus mostly disappeared, there are not enough live examples of disease to effectively test it, according to multiple reports.
#Could Dissolvable Microneedles Replace Injected Vaccines? Osaka University Study Eric is terrified. He stands outside the clinic and takes a few deep breaths before walking slowly through the automatic doors.
and studies suggest that around 1 in 12 people cite fear as their reason for not getting vaccinated.
A new vaccine delivery system could solve this problem: dissolvable microneedle patches are simple to use, pain-free and effective.
Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine,
The authors of the study, from Osaka University in Japan, say their dissolvable patch the only vaccination system of its kind could make vaccination easier, safer and less painful.
Downsizing to address the needle problem Most vaccines are injected under the skin or into the muscle using needles.
often causing them to avoid vaccination. The new microneedle patch is made of dissolvable material, eliminating needle-related risks.
where healthcare resources are limited. ur novel transcutaneous vaccination using a dissolving microneedle patch is the only application vaccination system that is readily adaptable for widespread practical use,
we believe it will be particularly effective in supporting vaccination in developing countries. The new microneedle patch Microhyala is dissolvable in water.
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
A/H1n1, A/H3n2 and B. None of the subjects had a bad reaction to the vaccine,
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection. e were excited to see that our new microneedle patch is
just as effective as the needle-delivered flu vaccines, and in some cases even more effective, said Dr. Nakagawa. e have shown that the patch is safe and that it works well.
Since it is also painless and very easy for non-trained people to use, we think it could bring about a major change in the way we administer vaccines globally.
New approaches to vaccination According to the World health organization immunization prevents an estimated 2 million to 3 million deaths every year.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Delivery methods that do not require needles are safer for the person administering the vaccine,
more pleasant for the person receiving the vaccine, and potentially less expensive. The challenge is developing a delivery method that gets the vaccine into the body effectively.
Microneedles provide one such delivery method, and they can be made of various different materials. Previous research has evaluated the use of microneedles made of silicon or metal
but they were shown not to be safe. Microneedles made from these materials also run the risk of breaking off in the skin, leaving tiny fragments behind;
For some diseases, vaccines may be more effective when theye absorbed through the mucous membranes in the nose.
For example, studies in mice have suggested that tuberculosis vaccines delivered through the noseare more effective than those that are injected,
either alone or as an adjunct to traditional parenteral methods of vaccine administration. e
#Bionic Hand Uses Smart Wires To Mimic Muscle fibers, Study Engineers in Germany have built a biologically inspired artificial hand with muscles made from bundles of'smart'wires.
or tracking vaccination campaigns in most resource-poor settings. It fantastic for an undergrad to be first author on the publication.
A single vaccine that immunizes against all types of influenza may soon be a reality,
Researchers said that the breakthrough could lead to the development of a vaccine that can fight all new influenza viruses. Professor Xu,
China, said this study would significantly enlighten T-cell based vaccine development and immune intervention during severe influenza infection in the future.
Vaccination will no longer be a painful process as researchers from Japan's Osaka University have developed a new technique that can deliver vaccines without needles.
The new method will encourage vaccination thus aiding in reducing global disease burden. The technique was found to be safe and effective in lab testssingapore:
Vaccination will no longer be a painful process as researchers from Japan's Osaka University have developed a new technique that can deliver vaccines without needles.
The new method will encourage vaccination thus aiding in reducing global disease burden. Through this technology, vaccines are delivered simply by laying a tiny patch onto a person's finger,
before it dissolves into their skin.""We were excited to see that our new microneedle patch is
just as effective as the needle-delivered flu vaccines, and in some cases even more effective,"said Professor Nakagawa, one of the authors of the Osaka University study.
linical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch,
#Approval for AIDS Vaccine at Canadian University The Food and Drug Administration has given Canadian researchers approval to test a vaccine for HIV/AIDS on humans.
a vaccine could be on the market in about five years. Similar to the approaches used to develop vaccines for polio, influenza, rabies and Hepatitis a,
the vaccine is the first based on a genetically modified, killed whole virus and is the only HIV vaccine currently under development in Canada,
and one of the only few in the world. Beginning next month a clinical trial on 40 HIV-positive volunteers will begin.
Following the trials, tests will begin on 6, 600 HIV-negative but high-risk category volunteers.
These tests will focus on immune responses and effectiveness of the vaccine in two more phases s
and specifically, annual vaccination efforts. The flu vaccine isn perfect, though. Influenza mutates rapidly, which means a new vaccine formulation is needed every year.
An international team of researchers has identified a new antibody that might give us the edge in this yearly arms race.
It bypasses the constantly changing surface markers and attacks a different part of the virus membrane.
So why is influenza such a tricky virus to vaccinate against? The virus has a jumble of proteins on its surface called hemagglutinin
A vaccine provides a template of antigens to train the immune response to recognize the new strains of influenza each year.
Doctors have to predict which strains will be most prevalent in the upcoming flu season to formulate the vaccine
which will go a long way toward clearing the virus. She also believes HIV vaccines in development could give patients an extra edge.
Even a vaccine that isn 100 percent effective at preventing transmission could boost a patient ability to destroy reactivated virus. However,
and there currently is no treatment or vaccine. We continue to study the virus to improve our understanding of how it works
#Dissolvable Microneedles May Herald New Age of Vaccine Delivery Scientists from Osaka University report that flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine.
The authors of the study (linical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch,
say their dissolvable patch could make vaccination easier, safer, and less painful. According to the World health organization, immunization prevents an estimated 2 million deaths every year.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Most vaccines are injected under the skin or into the muscle using needles. While this is an effective delivery method,
"Our novel transcutaneous vaccination using a dissolving microneedle patch is the only application vaccination system that is readily adaptable for widespread practical use,
we believe it will be particularly effective in supporting vaccination in developing countries.""The new microneedle patch (Microhyala) is dissolvable in water.
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
and B. None of the subjects had a bad reaction to the vaccine, showing that it is safe to use in humans.
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection."
just as effective as the needle-delivered flu vaccines, and in some cases even more effective,"said Dr. Nakagawa.
we think it could bring about a major change in the way we administer vaccines globally, "said Dr. Nakagawa a
#Biopharma Demand Is Driving the Cell Culture Market The production of biologic therapies such as vaccines, blood factors,
Market Drivers An important driver of the cell culture market is the production of seasonal influenza vaccines,
as well as pandemic vaccine candidates. Seasonal influenza vaccines have traditionally been produced using egg-based technology. However, this labor-intensive approach to vaccine development is currently being replaced by cell-culture systems.
Prefluce, the first cell culture-based vaccine, received European approval in March 2011 and was available for the 2011012 influenza season in the 13 participating European union countries.
On November 20 2012, the U s. Food and Drug Administration approved the use of Flucelvax, which is the first U s.-licensed (trivalent inactivated) influenza vaccine manufactured using cell culture technology.
Stem cell research will also add to the robust growth of the cell culture market. The growing use
and diverse applications of stem cells are having a significant impact on the media market,
#Merck-Newlink Genetics Ebola Vaccine Shows 100%Efficacy in Phase III Trial Merck & co. and Newlink Genetics said today that a single dose of their Ebola vaccine candidate rvsv
-ZEBOV showed 100%efficacy in an analysis of interim data from a Phase III ring vaccination trial in Guinea.
According to those findings, all individuals who received the vaccine were protected against Ebola virus infection within 6 to 10 days of vaccination. he results of this interim analysis indicate that rvsv-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease
when delivered during an Ebola virus disease outbreak via a ring vaccination strategy, the study team concluded.
and July 20, 2015,4, 123 people were assigned randomly to immediate vaccination with rvsv-ZEBOV, while 3, 528 people were assigned randomly to delayed vaccination during the trial, named bola ça suffit, French for bola,
that enough. n the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomization,
whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters,
showing a vaccine efficacy of 100%,the researchers added. The international team carrying out the trial included researchers from the World health organization, the Norwegian Institute of Public health, the Health Ministry of Guinea,
and Médecins sans Frontières. he extraordinary efforts of the team in Guinea and other experts have yielded interim results that suggest a potential role for our rvsv-ZEBOV vaccine in the fight against Ebola disease, Roger
M. Perlmutter, M d.,Ph d, . president of Merck Research Laboratories, said a statement. Added Charles J. Link Jr.
e hope that the interim data published today contribute to the successful registration of our vaccine candidate,
The Sierra leone Trial to Introduce a Vaccine against Ebola (STRIVE) Phase III study being conducted by the Sierra leone College of Medicine and Allied Health Sciences, Sierra leone Ministry of Health,
The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase II study being conducted by a Liberia-NIH partnership in Liberia.
To date, the rvsv-ZEBOV vaccine has been administered to more than 9, 000 people in Phase I, II,
Vaccinated individuals have been shown to develop antibodies against the Ebola virus, but the significance and durability of this immune response have not been determined. rvsv-ZEBOV was engineered initially with support from the Public health Agency of Canada
To produce the vaccine, the vesicular stomatitis virus was weakened by removing a gene and replacing it with a single Ebola virus gene that alone cannot cause the disease.
Newlink also said it was tiered eligible for royalties on sales of the vaccine n certain markets, subject to certain conditions.
Major funding for these studies has come from sources that include the U s. Department of defense Defense Threat Reduction Agency and Joint Vaccine Acquisition Program, the U s. Department of health and Human Service Biomedical Advanced Research Development Authority,
and research related to the Ebola vaccine candidate, but primarily due to clinical trial expenses related to its pipeline of product candidates, including its Hyperacute immunotherapy cancer programs and its IDO pathway inhibitor (indoximod) programs
or READ more at Daily mail) Pass on the Good Newsbelow) TAGSBREAKTHROUGHHEALTHINNOVATIONMEDICALSCIENCEWELLNESS Cuban Cancer Vaccine Could Soon be Available in U s. May 20,
#World First Malaria Vaccine Approved and it Will be Not-for-Profit The world first malaria vaccine has been given approval by a European medical agency for future use in Sub-saharan africa, where more than a quarter million children under the age of five die every year from the disease.
European regulators examined phase III clinical trial results involving more than 16,000 young children conducted by research centers in eight African countries (Burkina faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria
Glaxosmithkline Vice president for Africa told CNN. t is the first time anyone ever has been able to make a vaccine against a parasite.
Perhaps most impressive, Glaxosmithkline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS, S available as a nonprofit drug.
with all that money going back into further research for a malaria vaccine that could be even more effective.
and expects to invest a further $200 to $250 million until the vaccine is ready for market.
With this approval from the European Medicines Agency Friday, the vaccine next will be considered by the World health organizations,
and if they will use the vaccine, along with current Malaria prevention techniques, like bed nets. 80%of the children involved in the clinical trials were protected also by insecticide treated bed nets.
malaria cases were reduced by almost half in children aged 5-17 months at the time of first vaccination and by 27%in infants aged 6-12 weeks.
000 clinical malaria cases were prevented over the study period for every 1, 000 children vaccinated
Administering a vaccine to protect against infection would overwhelm the patient's immune system. However, if he or she has the option of receiving an antiviral to eliminate the infection,
News and information A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015discoveries A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015announcements A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015interviews/Book reviews/Essays/Reports/Podcasts/Journals/White papers A step towards a type 1 diabetes vaccine by using nanotherapy June 10th,
#Freshly squeezed vaccines (Nanowerk News) MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune systems B cells,
and implementing antigen-presenting cell vaccines. Such vaccines, created by reprogramming a patients own immune cells to fight invaders,
hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic,
While most of these vaccines are created with dendritic cells, a class of antigen-presenting cells with broad functionality in the immune system,
A new vaccine-preparation approach Dendritic cells are the most naturally versatile antigen-presenting cells.
when for cell-based vaccines: They have a short lifespan, they do not divide when activated,
which has limited options for B-cell-based vaccine programming. Using Cellsqueeze circumvents this problem and by being able to separately configure delivery and activation,
researchers have greater control over vaccine design. Gail Bishop, a professor of microbiology at the University of Iowa Carver School of medicine and director of the schools Center for Immunology and Immune-Based Diseases, says that this paper presents a creative new approach with considerable
potential in the development of antigen-presenting cell vaccines. The antigen-presenting capabilities of B cells have often been underestimated,
in this new study, demonstrates promise as a versatile platform for creating more effective cell-based vaccines.
Future steps The researchers say they now plan to refine their B-cell-based vaccine to optimize distribution and function of the immune cells in the body.
A b-cell-based approach could also reduce the amount of patient blood required to prepare a vaccine.
patients receiving cell-based vaccines must have drawn blood over several hours each time a new dose must be prepared.
and cost required to engineer cell-based vaccines. We envision a future system, if we can take advantage of its microfluidic nature,
run it through a bedside device that has the antigen you want to vaccinate against, and then youd have the vaccine,
Szeto says s
#Nanotechnology helps protect patients from bone infection Leading scientists at the University of Sheffield have discovered nanotechnology could hold the key to preventing deep bone infections,
as guinea pigsvicious vaccine culture war now being waged against informed, intelligent Americans who seek to protect their children from deadly side effects131 Ways for an Infant to Die:
Vaccines and Sudden Deathnaturalnews exclusive: Michigan government unleashes armed raids on small pig farmers, forces farmer to shoot all his own pigs/**CONFIGURATION VARIABLES:
as a result of an infection and those triggered by a vaccine. Instead the technique might be useful in outbreaks of new viruses. Understanding how our immune system responds to other viral fragments might reveal clues as to
The vaccination drive has been dogged by political corruption rumours the vaccine was contaminated with HIV and violence nine health workers were killed by terrorist group Boko Haram in 2013.
Nigeria has come close to eradicating the disease several times before, only for it to re-emerge. But this is the longest the country has gone without reporting a case,
Both Afghanistan and Pakistan are making progress with their vaccination campaigns, but too many children are missed, partly due to the difficulties in reaching people in rural areas with poor infrastructure,
A lack of international funding for the vaccination campaigns is also a problem, says Rosenbaum.
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011